Rodenstock Wins German Innovation Award 2025 Amid Strong Financial Growth
Rodenstock has been awarded the prestigious German Innovation Award 2025 in the "Excellence in Business to Consumer – Medical Health" category for its groundbreaking B.I.G. EXACT® Sensitive lenses. The award win caps a robust financial year, marked by steady revenue growth and strategic product innovation.
The German Innovation Award, presented by the German Design Council, recognises products and solutions that deliver exceptional user value and pioneering innovation. Rodenstock’s B.I.G. EXACT® Sensitive lenses impressed the interdisciplinary jury with their unique combination of biometric data integration and personalised visual experience, offering wearers smoother dynamic vision, improved reading flow, and enhanced orientation.
"We are delighted to have received the German Innovation Award, which recognizes our innovative strength. It enables us and our partner opticians to raise awareness for the topic of "biometric vision" among spectacle wearers," says Sara Sydow, Director Marketing DACH at Rodenstock. Dr. Dietmar Uttenweiler, Executive Vice President Innovation at Rodenstock, added, "With this award, we are making our latest innovation and the pioneering technology with which B.I.G. EXACT® Sensitive offers spectacle wearers an even more natural visual experience much more visible. For us, this is a further step towards our vision - to provide everyone with the best vision."
The recognition follows an impressive financial performance in 2024, with Rodenstock reporting a 1.2% increase in revenue to €512.4 million, despite global macroeconomic pressures. The company also posted an adjusted EBITDA growth of €6.3 million, reaching €128.6 million, reflecting a 5.1% year-over-year increase.
This growth was fueled by strong demand for the B.I.G. VISION® product portfolio and a 62% year-over-year surge in global sales of MyCon™ lenses, which are specifically designed to manage myopia progression in children. The successful rollout of the DNEye® Scanner 3 further strengthened Rodenstock’s market position as a Med-Tech innovator.
Marcus Desimoni, CEO of the Rodenstock Group, says: "I would like to thank the entire team for another successful year, especially regarding great benefits for customers that result in very satisfied customers. With the strong performance of our B.I.G. VISION® portfolio, MyCon™ lenses and the strategic launch of the DNEye® Scanner 3, we have reached key milestones in our strategy. These achievements provide a strong foundation for further growth."
With operations in more than 85 countries and six centralised production facilities, Rodenstock continues to set benchmarks in individualised lens technology, reinforcing its mission of delivering "B.I.G. VISION® FOR ALL."
